Remove Clinic Remove Disease Remove Download
article thumbnail

ConcertAI's TeraRecon, Integrates Clinical and Generative AI, Supporting Clinical Research and Advancing Clinical Care Solutions at RSNA23

Imaging Technology

milla1cf Mon, 11/27/2023 - 14:13 November 27, 2023 — ConcertAI 's TeraRecon , the advanced visualization and clinical AI leader, recently unveiled first-in-category capabilities in advanced visualization, AI, and expansions to its AI partner ecosystem to enhance research capabilities and support complex clinical study workflows.

Clinic 52
article thumbnail

Median Technologies’ Head of Imaging Lab, Sebastien Jacques, explores 5 Transformative Ways AI-Powered Imaging Can Positively Impact Oncology Clinical Trials

Median

The world of clinical research is witnessing a remarkable transformation with the advent of artificial intelligence (AI) technologies. One area where AI is making a profound impact is in oncology clinical trials, particularly in the realm of medical imaging.

Clinic 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

REBEL Core Cast 107.0 – Vertebral Osteomyelitis

REBEL EM

Take Home Points Clinical presentation is very nonspecific; evaluate all patients presenting with back pain for infectious risk factors. MRI is key to diagnosis, obtain this imaging in all patients who raise clinical suspicion Patients with hemodynamic instability and neurologic compromise warrant empiric antibiotics.

Myelogram 104
article thumbnail

[Podcast] – Decoding Radiomics: The Future of Medical Imaging powered by AI

Median

Our podcast series uncovers insights from the imaging experts at Median Technologies, focusing on various topics related to medical imaging in oncology clinical trials. We recently recorded a conversation with Fadila Zerka , Clinical Research Scientist at Median Technologies. Hosted by Connor Anderson , U.S. Click here!

article thumbnail

REBEL Core Cast 114.0 – Carbon Monoxide Toxicity

REBEL EM

The symptoms of mild, acute exposure are non-specific and can be confused with a variety of other disease processes including common viral syndromes. Goldbaum 1976 ) Clinical Manifestations Acute, mild toxicity presents non-specifically. Testing is done via co-oximetry which determines the amount of carboxyhemoglobin in the blood.

Disease 105
article thumbnail

REBEL Core Cast 105.0 – Methylxanthine Toxicity

REBEL EM

The three main mechanisms that account for the clinical presentation of methylxanthine toxicity are: catecholamine release, adenosine antagonism, and phosphodiesterase inhibition. Clinical Manifestations Beta agonism will lead to hyperlactatemia, hypokalemia, hyperglycemia, and tachycardia. albuterol) and anti-cholinergics (ie.

Clinic 98
article thumbnail

REBEL Core Cast 85.0 – Superficial Venous Thrombosis

REBEL EM

REBEL Core Cast 85.0 – Superficial Venous Thrombosis Click here for Direct Download of the Podcast Definition: The presence of a clot in a superficial vein. Diagnosis Clinical diagnosis involves visualizing an area of redness and swelling and palpating a painful cord along the path of a vein. J Vasc Surg 1998, 27:338– 343.

Disease 52